Vertex Pharmaceuticals (VRTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX)

VRTX 437.17

+0.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (403)	3/7/2000 8:05:00 PM
From: Miljenko Zuanic	Read Replies (1) of 1169

Refractory ovarian/breast cancer seams to be reasonable target for INCEL/Taxol registrational PIII trial(s). So far +12% and +15% overall response rate isn't earth-shaking but do live bit of the hope that combination my work for specific pts. However, BCHE do not think the some. They have their own MDR candidate and it may explain their position on INCEL.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next